EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

BEYOND THE ANTICIPATED: “MONTELUKAST AND DELIRIUM” – A CASE REPORT

Breezy Ani Sam*, Nayana Rachel Koshy and Dr. Sara Kurien K., Dr Jaico Paulose

ABSTRACT

Montelukast is a leukotriene receptor antagonist (LTRA) that, in contrast to other airway receptors such as prostanoid, cholinergic, or beta-adrenergic receptors, exclusively targets cysteinyl leukotriene receptor type-1 by preventing LTD4 mediated bronchoconstriction with dosages as low as 5 mg. Behavioral alterations with Montelukast administration have been shown in several human trials. Psychotic symptoms, such as hallucinations, insomnia, nightmares, anxiety, aggressiveness and headache are seen in adults and children after taking medicine and stop when Montelukast therapy is withdrawn. We discuss one such instance of Montelukast induced delirium.

Keywords: Montelukast, Leukotriene receptor antagonist, Delirium, Neuropsychiatric adverse effects.

[Full Text Article] [Download Certificate]